Literature DB >> 10029891

[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].

R A Hanel1, M C Sandmann, M Kranich, P R De Bittencourt.   

Abstract

The neuroleptic malignant syndrome (NMS) consists in an idiosyncratic reaction to neuroleptic drugs, probably related to a blockage of dopamine receptors in basal ganglia. Research criteria for diagnosing NMS from DSM-IV require severe rigidity and fever accompanied by 2 of 10 minor features including diaphoresis, dysphagia, tremor, incontinence, altered mentation, mutism, tachycardia, elevated or labile blood pressure, leukocytosis and elevation of creatine phosphokinase. From a clinical point of view, the NMS may range a large spectrum of presentations. Haloperidol is the most frequent drug associated with this syndrome. We report the case of a 30 year-old man who developed NMS at two different occasions, the first related to haloperidol and chlorpromazine and the second related to olanzapine, to our knowledge without previous mention in the indexed literature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10029891     DOI: 10.1590/s0004-282x1998000500022

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  Sudden discontinuation and reinstitution of olanzapine-associated atypical neuroleptic malignant syndrome in a patient undergoing lung surgery.

Authors:  Zhiyong Zhao; Hua Zhang; Shaohua Wang; Xiaofeng Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 2.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome?

Authors:  Vassilis P Kontaxakis; Beata J Havaki-Kontaxaki; Nikolaos G Christodoulou; Konstantinos G Paplos; George N Christodoulou
Journal:  Ann Gen Hosp Psychiatry       Date:  2003-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.